Catalent (NYSE:CTLT) Given “Neutral” Rating at Robert W. Baird

Robert W. Baird restated their neutral rating on shares of Catalent (NYSE:CTLT) in a research note released on Tuesday morning, Benzinga reports. The firm currently has a $63.50 price target on the stock.

CTLT has been the subject of a number of other reports. William Blair restated a market perform rating on shares of Catalent in a report on Tuesday, September 3rd. Barclays increased their price objective on Catalent from $47.00 to $63.00 and gave the company an equal weight rating in a report on Friday, June 28th. StockNews.com initiated coverage on Catalent in a report on Wednesday, September 18th. They issued a sell rating for the company. Finally, Royal Bank of Canada restated a sector perform rating and issued a $63.50 price objective on shares of Catalent in a report on Thursday, July 11th. One analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of Hold and a consensus price target of $59.83.

Catalent Stock Up 0.7 %

Shares of NYSE:CTLT opened at $60.29 on Tuesday. The company has a fifty day moving average of $59.64 and a 200-day moving average of $57.31. The company has a market capitalization of $10.91 billion, a PE ratio of -9.88, a price-to-earnings-growth ratio of 2.32 and a beta of 1.15. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52. Catalent has a 52-week low of $31.80 and a 52-week high of $61.20.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Thursday, August 29th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.13. The company had revenue of $1.30 billion during the quarter, compared to the consensus estimate of $1.23 billion. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. On average, equities analysts predict that Catalent will post 0.85 EPS for the current fiscal year.

Insider Buying and Selling at Catalent

In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of the company’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the sale, the chief executive officer now owns 177,521 shares of the company’s stock, valued at $10,431,133.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Ricky Hopson sold 662 shares of the stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $59.56, for a total transaction of $39,428.72. Following the transaction, the insider now owns 29,974 shares of the company’s stock, valued at approximately $1,785,251.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Alessandro Maselli sold 9,088 shares of the stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $58.76, for a total transaction of $534,010.88. Following the transaction, the chief executive officer now directly owns 177,521 shares in the company, valued at approximately $10,431,133.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 13,409 shares of company stock valued at $782,923. 0.31% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Catalent

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Nisa Investment Advisors LLC boosted its position in shares of Catalent by 1.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company’s stock worth $619,000 after purchasing an additional 185 shares in the last quarter. Lindbrook Capital LLC boosted its position in shares of Catalent by 79.4% during the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after purchasing an additional 208 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Catalent by 25.9% during the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after purchasing an additional 212 shares in the last quarter. Czech National Bank boosted its position in shares of Catalent by 0.7% during the 1st quarter. Czech National Bank now owns 31,801 shares of the company’s stock worth $1,795,000 after purchasing an additional 228 shares in the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in Catalent by 1.4% in the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,238 shares of the company’s stock valued at $1,082,000 after acquiring an additional 257 shares in the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.